Abstract #0830
PSMA-PET vs mpMRI in prostate cancer patients with biochemical recurrence
Ingerid Skjei Knudtsen1, Bendik Skarre Abrahamsen1, Kirsten Margrete Selnæs2, Mattijs Elschot1, Sverre Langorgen3, Thomas Morten Keil3, Håkon Johansen3, Helena Bertilsson4,5, Dag Linthoe Halvorsen4, Torgrim Tandstad5,6, and Tone Frost Bathen1
1Department of Circulation and Medical Imaging, Norwegian University of Science and Technology, Trondheim, Norway, 2Department of Nuclear Medicine and Medical Physics, St. Olavs Hospital, Trondheim University Hospital, Trondheim, Norway, 3Department of Radiology and Nuclear Medicine, St. Olavs Hospital, Trondheim University Hospital, Trondheim, Norway, 4Department of Urology, St. Olavs Hospital, Trondheim University Hospital, Trondheim, Norway, 5Department of Clinical and Molecular Medicine, Norwegian University of Science and Technology, Trondheim, Norway, 6Cancer Clinic, St. Olavs Hospital, Trondheim University Hospital, Trondheim, Norway
Synopsis
The PSMA prostate recurrence study is a multisenter prospective trial where the overall aim is to evaluate the diagnostic accuracy of 18F/68Ga-PSMA PET for detection of disease in patients with biochemical recurrence. In this preliminary analysis, we have compared the clinical imaging report of PET/CT/mpMRI to a separate evaluation of mpMRI where the radiologist was blinded to the PET results. Of 94 patients included so far, recurrent disease and/or distant metastasis was detected in 44 % (median PSA 0.4 ng/ml), according to the imaging protocol while the detection rate was 17 % for the mpMRI study scoring.
This abstract and the presentation materials are available to members only;
a login is required.
Join Here
